Abstract
3603 Background: KRAS mutations negatively affect outcome after cetuximab (CTX) in metastatic colorectal cancer (mCRC). As only 20% of KRAS wild-type (WT) patients respond it is possible that other mutations, constitutively activating the EGFR pathway, are present in the non-responding WT. We retrospectively correlated KRAS, BRAF and PI3K mutational status with the clinical outcome of 64 mCRC patients treated with CTX plus chemotherapy. Methods: DNA was extracted from 5 mM paraffin-embedded sections containing at least 50% of tumoral cells, derived from primary or metastatic lesions. Exon 2 of KRAS and exon 15 of BRAF were amplified by PCR and analysed by direct sequencing. PIK3CA status was analysed by Pyrosequencing. A two-sided Fisher's exact test was used to evaluate the association between mutations and objective response (OR). Progression-free survival (PFS) was estimated by Kaplan-Meier method and curves were compared by log-rank test. Hazard ratios (HR) were estimated according to Cox multiple regression model. Results: Patient characteristics were as follows: Male/Female = 35/29; primary site: rectum/colon =13/51. KRAS, BRAF and PI3K mutations were present in 28.1%, 21.3% and 15.1% of CRC lesions, respectively. KRAS WT/MUT was associated with OR 28.3/22.2% (p=0.75), median PFS 5.1 (95% CI 3.3-6.2)/3.1 months (95%CI 2.3-5.5), p=0.85. BRAF WT/MUT was associated with OR 33.3/7.7% (p=0.08), PFS 5.1 (95% CI 2.9-6.5)/3.4 months (95%CI 1.4-5.1), p<0.01. PI3K WT/MUT was associated with OR 31.1/12.5% (p=0.41), PFS 5.3(95% CI 3.6-6.5)/2.2 months (95% CI 1.1-3.3), p<0.01. PFS (95% CI) was increasingly worse for patients with tumors harboring none, 1, or ≥ 2 molecular alteration(s): 5.5 (2.7-8.7), 3.5 (2.3-5.5), 2.1 months (1.0-3.9), respectively, p<0.01. Moreover, the multivariate analysis of PFS indicated BRAF and PI3K as potential independent predictors of clinical benefit: HR (95% CI) 2.74 (1.37-5.45), p<0.01 and 3.57 (1.45-8.80), p<0.01, respectively. Conclusions: Our results seem to confirm that comprehensive molecular dissection of the EGFR signaling pathways should be considered to better select mCRC patients for CTX based therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.